ARA-290
MetabolicFor metabolic-syndrome, type-2-diabetes-spectrum, and obesity-medicine indications, ARA-290 is one component in a multi-layer protocol. Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis.. CGM-tracked individual response in the first cycle, paired with adequate protein intake and resistance training, is the practical framework for evaluating whether ARA-290 contributes meaningfully at the 4 mg 1x daily subq dose.
Key Takeaways
Metabolic lens: ARA-290 is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers. Mechanism: Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle. Metabolic dose: 4 mg 1x daily subq via subq. Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.
Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis. The metabolic medicine framework evaluates ARA-290 against four pathway-level endpoints: insulin signalling and glycemic control, AMPK and mitochondrial function, visceral fat and cardiometabolic risk, and the appetite-satiety axis. The subsections below cover each.
Visceral fat and the cardiometabolic axis
ARA-290's effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral adipose effects emerge gradually over months of consistent dosing rather than acutely. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.
Weight management and the appetite circuit
Direct appetite effects are not the principal mechanism, but downstream effects on inflammation and metabolic flexibility translate into sustainable rather than rapid weight management. Pairing with adequate protein intake and resistance training is the standard approach for users targeting weight reduction.
Insulin signalling and glycemic effect
ARA-290's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.
In the metabolic syndrome population, ARA-290 for cardiometabolic risk produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
Where ARA-290 is used for type 2 diabetes research, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
ARA-290 for insulin sensitivity is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.
In the metabolic syndrome population, ARA-290 for glp-1 synergy produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 4 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 2 mg | 4–6 weeks initial cycle |
| Metabolic focus | SubQ | 4 mg | 1x daily SubQ |
| Maintenance phase | SubQ | 3 mg | Ongoing with periodic pauses |
Dose timing for ARA-290 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
ARA-290 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.
- ARA-290 + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with ARA-290's mechanism in metabolic / endocrine protocols.
- ARA-290 + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with ARA-290's mechanism in metabolic / endocrine protocols.
- ARA-290 + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with ARA-290's mechanism in metabolic / endocrine protocols.
- ARA-290 + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with ARA-290's mechanism in metabolic / endocrine protocols.
Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions.
Lens-specific safety considerations for metabolic / endocrine use of ARA-290: Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| ARA-290 | EPO-derived tissue-protective peptide | ~2 min plasma; long tissue effect | Metabolic |
| Semaglutide (GLP-1) | GLP-1 receptor agonist | ~7 days | The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding |
| Cagrilintide | Long-acting amylin analogue | ~7 days | A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone |
| Tesamorelin | Stabilised GHRH analogue | ~30 min | An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction |
Is ARA-290 appropriate alongside metformin or other diabetes medications?
How does ARA-290 affect glycemic control?
Will I regain weight after stopping ARA-290?
Will ARA-290 affect my muscle mass during weight loss?
What should I look for in ARA-290 sourcing and quality?
What route should I use for ARA-290?
Start a ARA-290 Protocol
Alukard provides physician-supervised metabolic protocols with GMP-certified ARA-290 and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
Get ProtocolQuick Facts
- Molecular weight
- 1257 Da
- Sequence length
- 11 aa
- Half-life
- ~2 min plasma; long tissue effect
- WADA
- Not specifically listed (EPO analogues require care)
- FDA
- Unapproved (Phase II/III in sarcoidosis & neuropathy)
- Research
- Multiple Phase II human trials
Stack Partners
All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for ARA-290 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Metabolic / Endocrine Protocol for ARA-290
Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
HIPAA Compliant · GMP Certified · Physician Supervised